Immunotherapy has improved patient outcomes in those with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) but less so in the neoadjuvant setting. Here, the authors report the efficacy, safety and exploratory biomarker analysis of a phase II clinical trial investigating neoadjuvant tislelizumab (anti-PD-1) and afatinib (EGFR TKI) in patients with locally advanced HNSCC.
- Zhi-gong Wei
- Hui-jiao Chen
- Xing-chen Peng
